LGALS3 and pancreatic adenocarcinoma: Galectin-3 has been involved as a major determinant of cold tumors (those which do not respond to immune checkpoint inhibitors due to the paucity of tumor T cell infiltration, as happens in prostate and pancreas adenocarcinomas); galectin-3 inhibition can reverse such resistance [363].